[HTML][HTML] Constant BCR-ABL transcript level≥ 0.1%(IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis
KM Poláková, V Polívková, J Rulcová, H Klamová… - Experimental …, 2010 - Elsevier
OBJECTIVE: Of 140 chronic myeloid leukemia patients responding to imatinib with complete
cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at≥ 0.1% level in a …
cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at≥ 0.1% level in a …
Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
Y Wei, M Hardling, B Olsson, R Hezaveh… - Annals of …, 2006 - Springer
Point mutations within the ABL kinase domain of the BCR-ABL gene are associated with
clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML). To obtain more …
clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML). To obtain more …
[HTML][HTML] In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and …
DW Sherbenou, MJ Wong, A Humayun, LS McGreevey… - Blood, 2005 - Elsevier
Background: Imatinib mesylate (IM) induces complete cytogenetic remission (CCR) in 82%
of newly diagnosed patients with CML in chronic phase. Most of these patients display …
of newly diagnosed patients with CML in chronic phase. Most of these patients display …
The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia
L Wang, K Knight, C Lucas, RE Clark - Haematologica, 2006 - haematologica.org
BCR-ABL kinase mutations may confer resistance to imatinib in patients with chronic
myeloid leukemia (CML), and may predict a poor outcome. We investigated whether rises in …
myeloid leukemia (CML), and may predict a poor outcome. We investigated whether rises in …
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
Mutations within the BCR-ABL kinase domain in imatinib-treated chronic myeloid leukemia
(CML) are the main mechanism of acquired resistance. The early detection of mutations …
(CML) are the main mechanism of acquired resistance. The early detection of mutations …
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate …
S Chu, H Xu, NP Shah, DS Snyder, SJ Forman… - Blood, 2005 - ashpublications.org
The BCR-ABL kinase inhibitor imatinib mesylate induces complete cytogenetic response
(CCR) in a high proportion of chronic myelogenous leukemia (CML) patients. However …
(CCR) in a high proportion of chronic myelogenous leukemia (CML) patients. However …
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate …
S Branford, Z Rudzki, S Walsh, I Parkinson, A Grigg… - Blood, 2003 - ashpublications.org
Imatinib-treated chronic myeloid leukemia (CML) patients with acquired resistance
commonly have detectable BCR-ABL kinase domain mutations. It is unclear whether …
commonly have detectable BCR-ABL kinase domain mutations. It is unclear whether …
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique
KA Kreuzer, P Le Coutre, O Landt, IK Na… - Annals of …, 2003 - Springer
Recently, various mutations within the Abl sequence have been described that negatively
affect imatinib binding to Bcr/Abl resulting in cellular resistance of chronic myeloid leukemia …
affect imatinib binding to Bcr/Abl resulting in cellular resistance of chronic myeloid leukemia …
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour, H Kantarjian, D Jones, M Talpaz, N Bekele… - Leukemia, 2006 - nature.com
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy
SG Willis, T Lange, S Demehri, S Otto, L Crossman… - Blood, 2005 - ashpublications.org
Mutations in the kinase domain (KD) of BCR-ABL are the leading cause of acquired imatinib
resistance. In some cases, identical mutations were detected at relapse and in …
resistance. In some cases, identical mutations were detected at relapse and in …